 SAN DIEGO, July 12, 2021 PRNewswire -- Halozyme Therapeutics, Inc. NASDAQ: HALO today announced that Janssen Biotech, Inc. Janssen received U.S. Food and Drug Administration FDA approval of DARZALEX FASPRO daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone Pd for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. The approval marks Janssens sixth indication for DARZALEX FASPRO in the treatment of multiple myeloma. 